Fig. 7: Synthesis of dPNAG-CRM197 conjugates as vaccine candidates. | Nature Communications

Fig. 7: Synthesis of dPNAG-CRM197 conjugates as vaccine candidates.

From: Poly-β-D-(1,6)-N-acetyl-glucosamine (PNAG) glycan vaccines with broad spectrum neutralizing activities

Fig. 7

Synthetic dPNAG glycans 41–49 were conjugated to CRM197, a nontoxic mutant of diphtheria toxin widely used as a carrier protein in licensed human vaccines, to enhance immunogenicity and support T-cell-dependent antibody responses. The conjugation was carried out using succinimidyl 3-(bromoacetamido)propionate (SBAP) to introduce thiol-reactive 2-bromoacetyl groups onto CRM197, followed by covalent coupling to dPNAG glycans bearing sulfhydryl functionalities to form stable thioether linkages. Residual reactive groups were quenched with cysteine to yield the final dPNAG glycan-CRM197 vaccine candidates 50–58.

Back to article page